NCT01288404

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Ramathibodi Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Detailed description

1. Impending recurrent pterygium 2. Anti-VEGF therapy * Bevacizumab * Subconjunctival injection * Suppress neovascularization

Conditions

• Pterygium of the Conjunctiva and Cornea

Interventions

Type	Name	Description
DRUG	Fluorometholone	topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
DRUG	Bevacizumab	subconjunctival bevacizumab 1.25 mg/0.05mL
DRUG	Bevacizumab	subconjunctival bevacizumab 2.5 mg/0.1mL
DRUG	Bevacizumab	subconjunctival bevacizumab 3.75 mg/0.15mL

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-09-01
• Completion: 2010-11-01
• First posted: 2011-02-02
• Last updated: 2011-02-02

Locations

1 site across 1 country: Thailand